Glycomine, a biotechnology startup, has raised $115 million in a Series C funding round to advance its lead program, GLM101, into a placebo-controlled Phase 2b clinical trial for PMM2-CDG, a rare genetic disorder. The trial aims to enroll between 40 to 50 participants and is expected to start in the middle of the year, with preliminary data anticipated in 2026. Attovia Therapeutics has secured $90 million in a Series C financing to further develop its immune-mediated disease pipeline. The funds will support the advancement of two lead candidates, ATTO-1310 and ATTO-3712, through clinical proof-of-concept and the expansion of its portfolio targeting inflammatory and immune diseases. Calidi Biotherapeutics has received FDA clearance for its Investigational New Drug (IND) application for CLD-201, an allogeneic stem cell-based immunotherapy aimed at treating solid tumors in adults, including breast cancer, head & neck cancer, and soft tissue sarcoma. Kairos Pharma has been awarded a Department of Defense grant to support its study of the lead compound ENV105, which aims to prevent drug resistance in lung cancer. The grant will help advance the research and development of this potential treatment. Galmed Pharmaceuticals has initiated a collaboration with Virginia Commonwealth University (VCU) to evaluate the effect of its drug Aramchol on overcoming drug resistance in gastrointestinal cancers. The study will focus on colorectal and liver cancers, aiming to improve treatment outcomes in these high-mortality diseases. Merida Biosciences has launched with a focus on developing Fc biotherapeutics to eliminate pathogenic autoantibodies for treating autoimmune diseases and allergies, introducing a novel precision immunology approach. BigHat Biosciences has extended its Series B funding from $75 million to over $120 million and entered into a partnership with Eli Lilly to develop AI-boosted antibodies. The company is preparing to enter the clinic next year. Earendil Labs has entered into a worldwide exclusive license agreement with Sanofi for two bispecific antibodies, HXN-1002 and HXN-1003, targeting autoimmune and inflammatory bowel diseases. The agreement includes an upfront payment of $125 million and potential milestone payments up to $1.72 billion. Adagio Medical Holdings has received FDA Breakthrough Device designation for its vCLAS cryoablation system, designed to treat drug-resistant ventricular tachycardia in patients with structural heart disease. The system is currently under evaluation in the FULCRUM-VT study.